Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

NCT01492686 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: MCI-186
DRUG: Placebo
DRUG: MCI-186 in open label phase

Sponsor

Tanabe Pharma Corporation